Scancell Ltd.
- Country
- π¬π§United Kingdom
- Ownership
- Public, Subsidiary
- Established
- 1996-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)β’ Click on a phase to view related trials
Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer
- Conditions
- Triple Negative Breast CancerRenal Cell CancerSquamous Cell Carcinoma of the Head and NeckHigh Grade Ovarian Serous Adenocarcinoma
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Scancell Ltd
- Target Recruit Count
- 144
- Registration Number
- NCT05329532
- Locations
- π¬π§
Brighton and Sussex University Hospital, Brighton, Default, United Kingdom
π¬π§University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, Default, United Kingdom
π¬π§Velindre Cancer Centre, Cardiff, Default, United Kingdom
A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection
- Conditions
- COVID-19
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Scancell Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT05047445
- Locations
- πΏπ¦
University of Cape Town Lung Institute, Centre for TB Research Innovation, Cape Town, Western Cape, South Africa
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
- Conditions
- Malignant MelanomaMelanoma (Skin)Melanoma Stage IVMelanoma Stage III
- Interventions
- Biological: SCIB1 or iSCIB1+ DNA vaccine
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Scancell Ltd
- Target Recruit Count
- 173
- Registration Number
- NCT04079166
- Locations
- π¬π§
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
π¬π§Velindre University NHS Trust, Cardiff, United Kingdom
π¬π§The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Study of a DNA Immunotherapy to Treat Melanoma
- Conditions
- Malignant Melanoma
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Scancell Ltd
- Target Recruit Count
- 35
- Registration Number
- NCT01138410
- Locations
- π¬π§
Department of Medical Oncology, The Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
π¬π§St James' Institute of Oncology, Leeds, United Kingdom
π¬π§Christie Hospital, Manchester, United Kingdom